Theralase Technologies (TLTF.F) Stock Overview
A clinical stage pharmaceutical company, engages in the research, development, and commercialization of energy activated small molecules and associated drug formulations in Canada, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
TLTF.F Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Theralase Technologies Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.19 |
| 52 Week High | CA$0.31 |
| 52 Week Low | CA$0.10 |
| Beta | 0.59 |
| 1 Month Change | 11.94% |
| 3 Month Change | -26.38% |
| 1 Year Change | 23.88% |
| 3 Year Change | -16.07% |
| 5 Year Change | -7.14% |
| Change since IPO | -0.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| TLTF.F | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 1.1% | -1.0% | -1.4% |
| 1Y | 23.9% | -21.8% | 16.4% |
Return vs Industry: TLTF.F exceeded the US Medical Equipment industry which returned -20.1% over the past year.
Return vs Market: TLTF.F exceeded the US Market which returned 17.3% over the past year.
Price Volatility
| TLTF.F volatility | |
|---|---|
| TLTF.F Average Weekly Movement | 17.6% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: TLTF.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: TLTF.F's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Roger Dumoulin-White | www.theralase.com |
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of energy activated small molecules and associated drug formulations in Canada, the United States, and internationally. The company operates in two segments, Drug Division and Device Division. It engages in the research and development of Rutherrin, an injectable form of Ruvidar for the treatment of glio blastoma multiforme, a form of brain cancer, non-small cell lung cancer, pancreatic cancer, colorectal cancer, and muscle invasive bladder cancer; and Ruvidar, a topical treatment for herpes simplex virus-1 lesions and an extracorporeal treatment for lymphoma, leukemia, and multiple myeloma.
Theralase Technologies Inc. Fundamentals Summary
| TLTF.F fundamental statistics | |
|---|---|
| Market cap | US$54.58m |
| Earnings (TTM) | -US$2.61m |
| Revenue (TTM) | US$609.13k |
Is TLTF.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TLTF.F income statement (TTM) | |
|---|---|
| Revenue | CA$857.91k |
| Cost of Revenue | CA$299.69k |
| Gross Profit | CA$558.22k |
| Other Expenses | CA$4.24m |
| Earnings | -CA$3.68m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.012 |
| Gross Margin | 65.07% |
| Net Profit Margin | -429.11% |
| Debt/Equity Ratio | 13.1% |
How did TLTF.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/22 18:12 |
| End of Day Share Price | 2026/07/22 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Theralase Technologies Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andre Uddin | Research Capital Corporation |